STOCK TITAN
  1. Home
  2. News
  3. OKYO

OKYO Pharma Limited - OKYO STOCK NEWS

Welcome to our dedicated news page for OKYO Pharma (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OKYO Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OKYO Pharma's position in the market.

News
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
Rhea-AI Summary
OKYO Pharma (OKYO) announces financial results for the twelve months ended March 31, 2023 and provides a corporate update on its lead program, OK-101, to treat dry eye disease. The company's CEO, Gary Jacob, expresses satisfaction with the progress made in the development of OK-101 and anticipates the release of top line data in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
-
News
OKYO Pharma Limited Announces Withdrawal of Public Offering
Rhea-AI Summary
OKYO Pharma has announced the withdrawal of its proposed public offering of ordinary shares due to changing market conditions. The decision was made in the best interest of the Company and its shareholders. CEO Gary Jacob stated that the focus remains on advancing research and development initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15%
Tags
offering
-
News
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
Rhea-AI Summary
OKYO Pharma announces its intention to sell ordinary shares in an underwritten public offering. The company expects to use the net proceeds primarily for clinical development, general corporate purposes, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
News
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
Rhea-AI Summary
OKYO Pharma Limited received a deficiency letter from the Nasdaq Stock Market stating that the market value of its ordinary shares had closed below the minimum $35 million requirement for continued inclusion on the Nasdaq Capital Market. OKYO has been given until January 22, 2024, to regain compliance with the Market Value Rule. If it fails to do so, its shares may be subject to delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center         
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.02%
Tags
clinical trial
-
News
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
Rhea-AI Summary
OKYO Pharma Limited has appointed William A. Clementi as Chief Operating Officer, effective September 1, 2023. Dr. Clementi brings extensive experience in the pharmaceutical industry and will contribute to the development of OKYO's first product for dry eye disease. CEO Gary Jacobs expressed enthusiasm for Dr. Clementi's appointment and expects his leadership to drive OKYO Pharma's growth and success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.28%
Tags
management
News
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.57%
Tags
clinical trial
-
News
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
-
News
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
Rhea-AI Summary
Goldman Small Cap Research has published a research report on OKYO Pharma Limited, an emerging player in the ophthalmic drugs segment. OKYO is focused on developing molecules for inflammatory dry eye diseases and chronic pain. Its lead candidate, OK-101, aims to treat dry eye disease, a $5.5 billion global market. OKYO has recently started a Phase II clinical trial in the US. Analysts believe OKYO's advantages over existing therapies could lead to a re-valuation of the stock and potential partnerships. The 6-9 month price target is based on forecasted sales and industry M&A activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.92%
Tags
none
News
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
none
Stock OKYO logo
OKYO Pharma Limited

Nasdaq:OKYO

OKYO Rankings

#4719 Ranked by Market Cap
#3813 Ranked by Stock Gains
N/A Ranked by Dividends

OKYO Stock Data

46.03M
13.64M
25.72%
2.53%
0.55%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Guernsey
Admiral Park